
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TJ108
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Samsung Bioepis
Deal Size : Undisclosed
Deal Type : Collaboration
Samsung Bioepis, Phrontline Partner on Antibody-Drug Conjugates
Details : The collaboration aims to advance the development of TJ108, an antibody-drug conjugate targeting TOP1i/Tubulin, for the treatment of cancers.
Product Name : TJ108
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 20, 2025
Lead Product(s) : TJ108
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Samsung Bioepis
Deal Size : Undisclosed
Deal Type : Collaboration
